<?xml version="1.0" encoding="UTF-8"?>
<p>In addition, 74 (67%) of the 110 patients who received the vaccine agreed to respond to our anonymous survey. All were men with a median age of 45 years (mean = 45 years; range: 17–71 years). They were HIV positive since a median duration of 7 years (mean = 7 years; range: 0–34 years). All were on cART, with a HIV RNA load &lt;35 copies/ml for 93% of them and a CD4 cell count &gt;500/mm
 <sup>3</sup> for 74%. With regard to their sexual behaviour, a majority of the 74 patients (
 <italic>n</italic> = 62; 84%) reported an active sexuality in the 2 previous months, mostly with male partners (
 <italic>n</italic> = 60; 81%) or partners of both sex (
 <italic>n</italic> = 5; 7%). During this period of time, 24 (32%) of the 74 patients had the same sexual partner. The other patients (
 <italic>n</italic> = 50; 68%) mentioned multiple sexual partners during the 2 previous months, with 2–5 partners for 36%, 5 to 10 partners for 13%, 10 to 30 partners for 10% and &gt;30 partners for 9%. The way for meeting their sexual partner was internet (application on mobile phone and meeting site) for 58% of the patients and dedicated party places for 31% (gay bars in 16%, backrooms in 5%, sauna in 9% and a public park in 9%). With regard to sexual practices during the 2 previous months, anal penetration was reported for 56 patients (76%), with a systematic condom use in 25 cases (34%). A total of 57 patients (77%) had oral sex, protected by a condom in two cases (3%). ChemSex was consumed monthly by two patients (3%), annually by eight (11%), while 21 patients (28%) were unaware of this practice. All 74 patients who responded to the survey had a history of another STD, including syphilis (
 <italic>n</italic> = 28; 38%), chlamydiosis (
 <italic>n</italic> = 19; 26%), gonorrhoeae (
 <italic>n</italic> = 17; 24%) and HBV or HCV infection (
 <italic>n</italic> = 11; 15%). Nevertheless, 30% of the surveyed patients had no idea of the routes of transmission of STD, including 31 (42%) regarding gonorrhoeae, 29 (39%) regarding chlamydiosis, 23 (31%) regarding HBV/HCV, 15 (20%) regarding syphilis and finally 15 (20%) regarding HAV.
</p>
